Skip to main content Skip to main navigation menu Skip to site footer

The role of methionine in tuberculosis and its potential clinical significance


Tuberculosis (TB) remains a significant global health challenge. Multidrug-resistant tuberculosis (MDR-TB) holds a substantial health risk, and only a limited number of patients receive treatment for drug-resistant tuberculosis. Various studies have been conducted to address this condition, including through metabolic approaches to further understand the mechanisms of tuberculosis infection, one of which is methionine. There are various enzymes in the Mycobacterium tuberculosis (MTB) methionine biosynthesis pathway, the key enzymes such as MetX, MetC, MetE/MetH, MetK, MTHFR, and BCAT are essential in the biosynthesis of methionine, and hindering these enzyme activities may hold potential for new antitubercular drug development. Deletion of the metA gene weakens MTB, making it more prone to host immune responses. There is also the role of cobalamin, where cobalamin availability regulates the choice between metE and metH in methionine biosynthesis. Methionine plays a crucial role in bacterial protein translation and antioxidant activities. In bacteria including MTB, the initial methionine is formulated; this process involves several enzymes such as FMT, MetRS, PDF, and MetAP. Some compounds targeting MetAP have been identified to have significant inhibitory action against MTB, such as transitmycin and bengamides, and this also includes the drug resistant strain. Methionine supplementation alongside vitamin B-complex have shown to improve drug-induced toxicity in tuberculosis patients, this due to methionine serves as precursor to antioxidant glutathione. Metabolomics studies have shown that altered methionine levels in tuberculosis infection, with samples taken from human blood or urine show significantly lower levels in patients with active TB or failed treatment groups. This review aims to discuss the role of methionine in Mycobacterium tuberculosis and the progress of research targeting methionine metabolism and function.



  1. Cempaka R, Nuryastuti T, Laiman V, Yuliani FS, Musthafa A, Pratiwi H, Maecellus, Heriyanto DS. High expression of early secretory antigenic target 6 mRNA as a potential predictor of tuberculous lymphadenitis. Bali Medical Journal. 2020;9(3):794-798.
  2. Dheda K, Perumal T, Moultrie H, et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respir Med. 2022;10(6):603-622.
  3. World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. 1–68 p.
  4. Hasenoehrl EJ, Rae Sajorda D, Berney-Meyer L, Johnson S, Tufariello JAM, Fuhrer T, et al. Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection. Nat Commun. 2019;10(1).
  5. Howe MD, Kordus SL, Cole MS, et al. Methionine Antagonizes para-Aminosalicylic Acid Activity via Affecting Folate Precursor Biosynthesis in Mycobacterium tuberculosis. Front Cell Infect Microbiol. 2018;8:399.
  6. Triwicaksana AAF, Rusli M, Arfijanto MV, Bramantono, Nasronudin, Hadi, U. A patient with CD4+ T cells deficiency and HIV negative with pulmonary tuberculosis, tuberculous pleuritis and meningitis tuberculosis. Bali Medical Journal. 2022;11(2):597-601.
  7. Chaton CT, Rodriguez ES, Reed RW, Li J, Kenner CW, Korotkov K V. Structural analysis of mycobacterial homoserine transacetylases central to methionine biosynthesis reveals druggable active site. Sci Rep. 2019;9(1):1–11.
  8. Vrieling F, Alisjahbana B, Sahiratmadja E, van Crevel R, Harms AC, Hankemeier T, et al. Plasma metabolomics in tuberculosis patients with and without concurrent type 2 diabetes at diagnosis and during antibiotic treatment. Sci Rep. 2019;9(1):1–12.
  9. Parbhoo T, Mouton JM, Sampson SL. Phenotypic adaptation of Mycobacterium tuberculosis to host-associated stressors that induce persister formation. Front Cell Infect Microbiol. 2022;12:956607.
  10. Ding Y, Raterink RJ, Marín-Juez R, Veneman WJ, Egbers K, van den Eeden S, et al. Tuberculosis causes highly conserved metabolic changes in human patients, mycobacteria-infected mice and zebrafish larvae. Sci Rep. 2020;10(1):1–13.
  11. Opperman M, Loots DT, Van Reenen M, Ronacher K, Walzl G, Du Preez I. Chronological Metabolic Response to Intensive Phase TB Therapy in Patients with Cured and Failed Treatment Outcomes. ACS Infect Dis. 2021;7(6):1859–69.
  12. Wang L, Ying R, Liu Y, Sun Q, Sha W. Metabolic Profiles of Clinical Isolates of Drug-Susceptible and Multidrug-Resistant Mycobacterium tuberculosis: A Metabolomics-Based Study. Infect Drug Resist. 2023;16:2667–80.
  13. Wei W, Yan H, Zhao J, et al. Multi-omics comparisons of p-aminosalicylic acid (PAS) resistance in folC mutated and un-mutated Mycobacterium tuberculosis strains. Emerg Microbes Infect. 2019;8(1):248-261
  14. Kelley BR, Callahan SM, Johnson JG. Transcription of Cystathionine β-Lyase (MetC) Is Repressed by HeuR in Campylobacter jejuni, and Methionine Biosynthesis Facilitates Colonocyte Invasion. J Bacteriol. 2021;203(15):e0016421.
  15. Amalius AA, Budu, Massi MN, Umar BT, Minhajat R, Muis M, Handayani I, Hidayah N. A systematic review of natural resistance-associated macrophage protein 1 (NRAMP1) gene and susceptibility to tuberculosis: What is the link for ocular tuberculosis?. Bali Medical Journal. 2023;12(3):3015-3025.
  16. Sagong HY, Hong J, Kim KJ. Crystal structure and biochemical characterization of O-acetylhomoserine acetyltransferase from Mycobacterium smegmatis ATCC 19420. Biochem Biophys Res Commun. 2019;517(3):399–406.
  17. Yu JF, Xu JT, Yang SS, Gao MN, Si HR, Xiong DY, et al. Decreased Methylenetetrahydrofolate Reductase Activity Leads to Increased Sensitivity to para-Aminosalicylic Acid in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2022;66(1):1–16.
  18. Maurya B, Pochet L, Wouters J, Colaço M, Misquith S. MetA (Rv3341) from Mycobacterium tuberculosis H37Rv strain exhibits substrate dependent dual role of transferase and hydrolase activity. Biochimie. 2020;179:113–26.
  19. Sharma S, Jayasinghe YP, Mishra NK, Orimoloye MO, Wong TY, Dalluge JJ, et al. Structural and Functional Characterization of Mycobacterium tuberculosis Homoserine Transacetylase. ACS Infect Dis. 2023;9(3):540–53.
  20. Chaudhary D, Singh A, Marzuki M, Ghosh A, Kidwai S, Gosain TP, et al. Identification of small molecules targeting homoserine acetyl transferase from Mycobacterium tuberculosis and Staphylococcus aureus. Sci Rep. 2022;12(1):1–16.
  21. Nzungize L, Ali MK, Wang X, Huang X, Yang W, Duan X, et al. Mycobacterium tuberculosis metC (Rv3340) derived hydrogen sulphide conferring bacteria stress survival. J Drug Target. 2019;27(9):1004–16.
  22. Kipkorir T, Mashabela GT, Wet TJ De, Koch A. De Novo Cobalamin Biosynthesis, Transport, and Assimilation and Cobalamin-Mediated Regulation of Methionine Biosynthesis in Mycobacterium smegmatis. J Bacteriol. 2021;1–16.
  23. Nieto LMR, Mehaffy C, Islam MN, Fitzgerald B, Belisle J, Prenni J, et al. Biochemical characterization of isoniazid-resistant Mycobacterium tuberculosis: Can the analysis of clonal strains reveal novel targetable pathways? Mol Cell Proteomics. 2018;17(9):1685–701.
  24. Kipkorir T, Mashabela GT, de Wet TJ, et al. De NovoCobalamin Biosynthesis, Transport, and Assimilation and Cobalamin-Mediated Regulation of Methionine Biosynthesis in Mycobacterium smegmatis. J Bacteriol. 2021;203(7):e00620-20.
  25. Gallant J, Heunis T, Beltran C, et al. PPE38-Secretion-Dependent Proteins of M. tuberculosis Alter NF-kB Signalling and Inflammatory Responses in Macrophages. Front Immunol. 2021;12:702359
  26. Pham MT, Tran TTA, Zayabaatar E. Discovery of inhibitors against mycobacterium branched‐chain amino acid aminotransferases through in silico screening and experimental evaluation. Lett Appl Microbiol. 2022;75(4):942–50.
  27. Allué-Guardia A, Saranathan R, Chan J, Torrelles JB. Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis. Int J Mol Sci. 2021;22(2):735.
  28. Sekowska A, Ashida H, Danchin A. Revisiting the methionine salvage pathway and its paralogues. Microb Biotechnol. 2019;12(1):77-97.
  29. Wang W, Qin B, Wojdyla JA, Wang M, Gao X, Cui S. Structural characterization of free-state and product-state Mycobacterium tuberculosis methionyl-tRNA synthetase reveals an induced-fit ligand-recognition mechanism. IUCrJ. 2018;5:478–90.
  30. Barros-Álvarez X, Turley S, Ranade RM, Gillespie JR, Duster NA, Verlinde CLMJ, et al. The crystal structure of the drug target Mycobacterium tuberculosis methionyl-tRNA synthetase in complex with a catalytic intermediate. Acta Crystallogr Sect F Struct Biol Commun. 2018;74(4):245–54.
  31. Volynets GP, Starosyla SA, Rybak MY, Bdzhola VG, Kovalenko OP, Vdovin VS, et al. Dual-targeted hit identification using pharmacophore screening. J Comput Aided Mol. 2019;33(11):955–64.
  32. Chaton CT, Rodriguez ES, Reed RW, Li J, Kenner CW, Korotkov KV. Structural analysis of mycobacterial homoserine transacetylases central to methionine biosynthesis reveals druggable active site. Sci Rep. 2019;9(1):20267.
  33. Reddi B, Kishor C, Jangam A, Bala S, Rajeswari Batchu U, Gundla R, et al. Regioselectivity in inhibition of peptide deformylase from Haemophilus influenzae by 4- vs 5-azaindole hydroxamic acid derivatives: Biochemical, structural and antimicrobial studies. Bioorg Chem. 2022;128:106095.
  34. Vanunu M, Schall P, Reingewertz TH, Chakraborti PK, Grimm B, Barkan D. MapB protein is the essential methionine aminopeptidase in Mycobacterium tuberculosis. Cells. 2019;8(5):1–12.
  35. Mondal R, Dusthackeer AVN, Kannan P, Singh AK, Thiruvengadam K, Manikkam R, et al. In-vivo studies on Transitmycin, a potent Mycobacterium tuberculosis inhibitor. PLoS One. 2023;18:1–17.
  36. Juhás M, Pallabothula VSK, Grabrijan K, Šimovičová M, Janďourek O, Konečná K, et al. Design, synthesis and biological evaluation of substituted 3-amino-N-(thiazol-2-yl)pyrazine-2-carboxamides as inhibitors of mycobacterial methionine aminopeptidase 1. Bioorg Chem. 2022;118:105489.
  37. Ekpenyong O, Gao X, Ma J, Cooper C, Nguyen L, Olaleye OA, et al. Pre-clinical pharmacokinetics, tissue distribution and physicochemical studies of CLBQ14, a novel methionine aminopeptidase inhibitor for the treatment of infectious diseases. Drug Des Devel Ther. 2020;14:1263–77.
  38. Quan DH, Nagalingam G, Luck I, Proschogo N, Pillalamarri V, Addlagatta A, et al. Bengamides display potent activity against drug-resistant Mycobacterium tuberculosis. Sci Rep. 2019;9(1):1–10.
  39. John SF, Aniemeke E, Ha NP, Chong CR, Gu P, Zhou J, et al. Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis. Tuberculosis. 2016;101(October):S73–7.
  40. Lim JM, Kim G, Levine RL. Methionine in Proteins: It's Not Just for Protein Initiation Anymore. Neurochem Res. 2019;44(1):247-257.
  41. Vincent MS, Ezraty B. Methionine oxidation in bacteria: A reversible post-translational modification. Mol Microbiol. 2022;:143–50.
  42. Moskovitz J, Smith A. Methionine sulfoxide and the methionine sulfoxide reductase system as modulators of signal transduction pathways: a review. Amino Acids. 2021;53(7):1011–20.
  43. Bandyopadhyay P, Pramanick I, Biswas R, Sabarinath PS, Sreedharan S, Singh S, et al. S-Adenosylmethionine–responsive cystathionine β-synthase modulates sulfur metabolism and redox balance in Mycobacterium tuberculosis. Sci Adv. 2022;8(25):1–20.
  44. Bockman MR, Engelhart CA, Cramer JD, et al. Investigation of ( S)-(-)-Acidomycin: A Selective Antimycobacterial Natural Product That Inhibits Biotin Synthase. ACS Infect Dis. 2019;5(4):598-617.
  45. Vanunu M, Schall P, Reingewertz TH, Chakraborti PK, Grimm B, Barkan D. MapB Protein is the Essential Methionine Aminopeptidase in Mycobacterium tuberculosis. Cells. 2019;8(5):393.
  46. Cho Y, Park Y, Sim B, Kim J, Lee H, Cho SN, et al. Identification of serum biomarkers for active pulmonary tuberculosis using a targeted metabolomics approach. Sci Rep. 2020;10(1):1–11.
  47. Sinclair LV, Howden AJM, Brenes A, Spinelli L, Hukelmann JL, Macintyre AN, et al. Antigen receptor control of methionine metabolism in T cells. Elife. 2019;8:8–10.
  48. Gröschel MI, Sayes F, Shin SJ, Frigui W, Pawlik A, Orgeur M, et al. Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection. Cell Rep. 2017;18(11):2752–65.
  49. Vilchèze C, Porcelli SA, Chan J, Jacobs WR. Sterilization by adaptive immunity of a conditionally persistent mutant of Mycobacterium tuberculosis. MBio. 2021;12(1):1–5.

How to Cite

Sari, P. S. ., Mas Rizky A A Syamsunarno, & Chaidir, L. . (2024). The role of methionine in tuberculosis and its potential clinical significance. Indonesia Journal of Biomedical Science, 18(1), 45–51.




Search Panel

Putu Suwita Sari
Google Scholar
IJBS Journal

Mas Rizky A A Syamsunarno
Google Scholar
IJBS Journal

Lidya Chaidir
Google Scholar
IJBS Journal